

# High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction

**Running Title:** *Chapman et al.; Classification of Myocardial Injury and Infarction*

Andrew R. Chapman, et al

*The full author list is available on page 17.*

**Address for Correspondence:**

Andrew R. Chapman, MD  
BHF/University Centre for Cardiovascular Science  
The University of Edinburgh  
Edinburgh EH16 4SA  
United Kingdom  
Telephone: +44 131 242 6515  
Fax: +44 131 242 6379  
Email: [a.r.chapman@ed.ac.uk](mailto:a.r.chapman@ed.ac.uk)



Circulation

## Abstract

**Background:** The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin (hs-cTn) testing and classification of patients with myocardial injury based on aetiology, but the clinical implications of implementing this guideline are not well understood.

**Methods:** In a stepped-wedge cluster randomized controlled trial, we implemented a hs-cTn assay and the recommendations of the Universal Definition in 48,282 consecutive patients with suspected acute coronary syndrome. In a pre-specified secondary analysis, we compared the primary outcome of myocardial infarction or cardiovascular death and secondary outcome of non-cardiovascular death at one year across diagnostic categories.

**Results:** Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4,471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial injury by 36% (443/1,233) and 43% (389/898), respectively. Compared to those without myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard ratio [csHR] 5.64, 95% confidence interval [CI] 5.12 to 6.22), but was similar across diagnostic categories, whereas non-cardiovascular deaths were highest in those with acute myocardial injury (csHR 2.65, 95%CI 2.33 to 3.01). Despite modest increases in anti-platelet therapy and coronary revascularization after implementation in patients with type 1 myocardial infarction, the primary outcome was unchanged (csHR 1.00, 95%CI 0.82 to 1.21). Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to changes in investigation, treatment or outcomes.

**Conclusions:** Implementation of high-sensitivity cardiac troponin and the recommendations of the Universal Definition of Myocardial Infarction identified patients at high-risk of cardiovascular and non-cardiovascular events, but was not associated with consistent increases in treatment or improved outcomes. Trials of secondary prevention are urgently required to determine whether this risk is modifiable in patients without type 1 myocardial infarction.

**Clinical Trial Registration:** URL: <https://clinicaltrials.gov> Unique Identifier: NCT0185212

**Key Words:** Myocardial injury; myocardial infarction; universal definition; troponin

### Non-standard Abbreviations and Acronyms:

ACE: Angiotensin-Converting Enzyme

ARB: Angiotensin Receptor Blocker

cTn: contemporary cardiac Troponin

csHR: cause-specific Hazard Ratio

High-STEACS: High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome

HR: Hazard Ratio

hs-cTn: high-sensitivity cardiac Troponin

hs-cTnI: high-sensitivity cardiac Troponin I

IQR: Inter-Quartile Range

MI: Myocardial Infarction

NHS: National Health Service

## Clinical Perspective

### What is new?

- No previous randomised controlled trials have evaluated the effect of implementing a high-sensitivity cardiac troponin assay and the recommendations of the Universal Definition of Myocardial Infarction on the investigation, treatment and outcomes of patients stratified according to the proposed diagnostic classification.
- We demonstrate that implementation of high-sensitivity cardiac troponin testing leads to a disproportionate increase in type 2 myocardial infarction and myocardial injury.
- We found all patients with myocardial injury and infarction are at increased future cardiovascular risk, irrespective of aetiology, despite an excess in non-cardiovascular death in patients with type 2 myocardial infarction and myocardial injury.


### What are the clinical implications?

- Clinicians should consider investigations to define coronary or structural heart disease in patients with type 2 myocardial infarction and myocardial injury
- The risk of future cardiovascular events should be evaluated on an individual patient basis using all available clinical information
- Until randomised controlled trials are available, secondary prevention therapies should be considered on a pragmatic basis with the aim of reducing future cardiovascular risk



## Introduction

The Universal Definition of Myocardial Infarction has evolved to accommodate improvements in the sensitivity of cardiac troponin assays.<sup>1-3</sup> This international guideline recommends the use of high-sensitivity cardiac troponin (hs-cTn) assays and the 99<sup>th</sup> centile upper reference limit as the diagnostic threshold for myocardial infarction.<sup>4-7</sup> It also recognises that myocardial injury occurs in many conditions other than acute coronary syndromes,<sup>8-11</sup> and therefore proposes additional criteria for the classification of patients with myocardial injury and infarction based on aetiology.<sup>2,12</sup>

Despite nearly half of all elevations in cardiac troponin occurring in patients with type 2 myocardial infarction or myocardial injury,<sup>13</sup> this classification and its consequences for patients are not well understood in practice. We recently reported the primary outcome from a  multicentre randomised controlled trial evaluating the impact of implementing a hs-cTnI assay on clinical outcomes in consecutive patients with suspected acute coronary syndrome.<sup>14</sup> The introduction of hs-cTn reclassified one in six patients with myocardial necrosis who were not identified by the previous generation troponin assay, but this was not associated with an improvement in outcomes. In this pre-specified secondary analysis of the trial, we report whether implementing hs-cTn testing and the recommendations of the Universal Definition of Myocardial Infarction led to changes in investigation, treatment and outcomes in patients stratified according to the proposed diagnostic classification.

## Methods

### Transparency and openness promotion

The trial makes use of multiple routine electronic health care data sources that are linked, deidentified and held in our national safe haven, which is accessible by approved individuals who have undertaken the necessary governance training. Summary data and the analysis code can be made available upon request from the corresponding author.

### Study Population and Trial Design

*High-Sensitivity Troponin in the Evaluation of patients with suspected Acute Coronary Syndrome (High-STEACS)* is a stepped-wedge cluster randomised controlled trial to evaluate implementation of a hs-cTnI assay and the recommendations of the Universal Definition of Myocardial Infarction in consecutive patients with suspected acute coronary syndrome, across ten secondary and tertiary care hospitals in Scotland. All patients attending the Emergency Department were screened for suspected acute coronary syndrome by the attending clinician at the time troponin was requested, using an electronic form integrated into the clinical care pathway. Patients were eligible for inclusion if they presented with suspected acute coronary syndrome and had paired cardiac troponin measurements from the standard care and trial assay. Patients were excluded if they had been admitted previously during the trial period or were not resident in Scotland.

### Randomisation

All sites reported cardiac troponin using a contemporary troponin assay and existing diagnostic threshold in a validation phase of at least 6 months, before being randomly allocated to early or late implementation of a high-sensitivity assay with sex-specific 99<sup>th</sup> centile thresholds as recommended by the Universal Definition (*Supplementary Appendix A*).

## Intervention

Cardiac troponin testing was performed at presentation and was repeated 6 or 12 h after the onset of symptoms at the discretion of the attending physician and in accordance with national guidelines.<sup>15</sup> In the validation phase, a contemporary cardiac troponin I (cTnI) assay (Abbott Laboratories, Abbott Park, IL, USA) was used to guide clinical decisions. The inter-assay coefficient of variation was determined at each site and was less than 10% at 40 ng/L (seven sites) and 50 ng/L (three sites). Only cTnI concentrations above these diagnostic thresholds were reported. During the implementation phase, a hs-cTnI assay (ARCHITECT<sub>STAT</sub> high-sensitive troponin I assay; Abbott Laboratories, Abbott Park, IL, USA) was used to guide clinical decisions. This assay has an inter-assay coefficient of variation of less than 10% at 4.7 ng/L, and a 99<sup>th</sup> centile upper reference limit of 34 ng/L in men and 16 ng/L in women.<sup>4</sup>



To support implementation, we provided written educational material and presentations at each site, and updated the electronic patient record to highlight the change in assay and diagnostic thresholds. Educational material on the new assay, decision thresholds, and on the classification of myocardial injury and infarction were presented at each Emergency Department handover (twice daily). A detailed summary of the trial procedures and intervention is available in *Supplementary Appendix A*.

## Adjudication of Myocardial Injury and Infarction

All diagnoses in patients with hs-cTnI concentrations above the 99<sup>th</sup> centile were adjudicated and classified according to the Third Universal Definition of Myocardial Infarction.<sup>1</sup> In this pre-specified secondary analysis, this classification was updated to the Fourth Universal Definition of Myocardial Infarction.<sup>2</sup> Two physicians independently reviewed all clinical information, blinded to study phase, with discordant diagnoses resolved by a third reviewer. Type 1

myocardial infarction was defined as myocardial necrosis (any hs-cTnI concentration above the sex-specific 99th centile with a rise and/or fall in hs-cTnI concentration where serial testing was performed) in the context of a presentation with suspected acute coronary syndrome with symptoms or signs of myocardial ischemia on the electrocardiogram. Patients with myocardial necrosis, symptoms or signs of myocardial ischemia, and evidence of increased myocardial oxygen demand or decreased supply secondary to an alternative condition without evidence of acute atherothrombosis were defined as type 2 myocardial infarction. Patients with hs-cTnI concentrations above the 99<sup>th</sup> centile without symptoms or signs of myocardial ischemia were classified as having myocardial injury. The final clinical diagnosis was also adjudicated according to prespecified criteria. All non-ischemic myocardial injury was classified as acute, unless a change of  $\leq 20\%$  was observed on serial testing,<sup>2</sup> or the final adjudicated diagnosis was chronic heart failure or chronic renal failure, where the classification was chronic myocardial injury. A detailed summary of the adjudication procedures is provided in *Supplementary Appendix B*.

### **Trial Outcomes**

We used regional and national registries to ensure complete follow-up for the trial population.<sup>16</sup> The primary outcome was myocardial infarction (type 1 or type 4b) or cardiovascular death at 1 year. Primary outcome events were adjudicated by a panel who were blinded to the index presentation and study phase (*Supplementary Appendix A*). Secondary outcomes included all-cause death, cardiovascular death, cardiac death, non-cardiovascular death, duration of stay, myocardial infarction (type 1 or type 4b), unplanned coronary revascularisation, hospitalisation for heart failure, ischemic stroke, major haemorrhage and unplanned hospitalisation.

## **Ethical Approval**

The study was approved by the Scotland A Research Ethics Committee, the Public Benefit and Privacy Panel for Health and Social Care, and by each National Health Service (NHS) Health Board. All data were collected prospectively from the electronic patient record, deidentified and linked within secure NHS Safe Havens.

## **Patient and public involvement**

Both patients and lay representatives were members of the trial steering committee for the *High-STEACS* clinical trial and all related studies (NCT:01852123) and were involved in the design, conduct and approval of this study.

## **Statistical Analysis**

Baseline characteristics were summarised for the study population and in groups according to the universal definition classification. We assessed agreement between adjudicators across diagnostic categories using Cohen's Kappa. Group-wise comparisons were performed using Chi-square, Kruskal Wallis or one-way analysis of variance tests as appropriate. In post-hoc analysis, we compared management by classification, with type 1 myocardial infarction as the reference group, including a Bonferroni correction for multiple testing. Based on prior observations of an excess in non-cardiovascular death in patients with type 2 myocardial infarction and myocardial injury,<sup>11</sup> we applied competing risks methodology in all analyses.<sup>17</sup> The risk of the primary outcome and competing risk of non-cardiovascular death was estimated using a cumulative incidence function.<sup>18</sup> Outcome rates were compared between groups using cause-specific hazard ratios obtained from a Cox regression model, with patients without myocardial injury as the referent group. The model was adjusted for age, sex, a history of ischemic heart disease or diabetes mellitus, renal function (creatinine concentration), time of presentation from the start



date of the trial, season, site of recruitment (as a random effect) and phase of the trial. Where data were missing for creatinine concentration (1.9%, 948/48,282) this was assumed to be at random, and multiple imputation was applied using chained equations with five imputations of the data set. We compared the rates of the primary outcome before and after implementation of the high-sensitivity assay by group using an identical Cox proportional hazards model, including additional terms for the log transformed peak troponin concentration and interaction terms for phase of the trial and diagnostic group. All analyses were pre-specified (*Supplementary Appendix C*) and performed in R (Version 3.5.1) using the *survival* and *cmprsk* packages.

## Results

### Trial Sites and Population

We enrolled 48,282 patients (61±17 years, 47% women) with suspected acute coronary syndrome across ten sites with 39% (18,978/48,282) and 61% (29,304/48,282) enrolled during the validation and implementation phase, respectively.

### Classification by the Universal Definition of Myocardial Infarction

During the index presentation, 21% (10,360/48,282) of patients had hs-cTnI concentrations above the 99<sup>th</sup> centile (*Figure 1*). It was possible to adjudicate the diagnosis in 88% (9,115/10,360) of patients (*Table S1*), and there was substantial agreement between adjudicators ( $K=0.75$ ). The adjudicated diagnosis was type 1 myocardial infarction in 55% (4,981/9,115), type 2 myocardial infarction in 12% (1,121/9,115), and acute or chronic myocardial injury in 18% (1,676/9,115) and 14% (1,287/9,115), respectively (*Table 1*). Diagnostic agreement was substantial in patients with type 1 myocardial infarction ( $K=0.78$ ) and myocardial injury ( $K=0.65$ ), but was lower in those with type 2 myocardial infarction ( $K=0.49$ ). Compared to the



Third Universal Definition,<sup>14</sup> adoption of the recommendations from the Fourth Universal Definition reclassified 15% (1,320/9,115) of patients, with the majority of those reclassified having chronic myocardial injury (**Figure S1**). The use of objective criteria for myocardial oxygen supply or demand imbalance as proposed in the Fourth Definition led to an improvement in diagnostic agreement in those with type 2 myocardial infarction ( $K=0.62$ ).

Compared to those with type 1 myocardial infarction, patients with type 2 myocardial infarction were older ( $74\pm 14$  versus  $68\pm 14$  years), were more likely to be women (55% versus 40%), and more likely to have a history of cardiovascular disease. Patients with acute or chronic myocardial injury were of similar age and sex to those with type 2 myocardial infarction. Peak troponin concentrations were higher in patients with type 1 myocardial infarction (855 ng/L, interquartile range (IQR) 104 to 6,775 ng/L) compared to type 2 myocardial infarction (125 ng/L, 48 to 604 ng/L) and either acute or chronic myocardial injury (74 ng/L, IQR 37 to 307 ng/L, and 55 ng/L, IQR 34 to 145 ng/L, respectively; **Table 1**).

### Management by classification

The majority of patients with type 1 myocardial infarction were started on anti-platelet or anti-coagulant therapy in the emergency department (55%), and had coronary angiography (59%) or percutaneous coronary intervention (41%) during the index presentation (**Table 2**). Patients were likely to receive additional treatments including single (67%) or dual (60%) anti-platelet, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (32%), beta-blocker (38%) or statin (35%) therapies. Fewer patients with type 2 myocardial infarction received anti-platelet or anti-coagulant therapy at presentation (26%), or underwent coronary angiography (10%) and percutaneous coronary intervention (2%,  $P<0.001$  for all). On discharge, patients with type 2 myocardial infarction were less likely to receive new treatment with single

(19%) or dual (10%) anti-platelet, ACE inhibitor or ARB (9%), beta-blocker (20%) or statin (6%) therapies ( $P < 0.001$  for all). Patients with acute or chronic myocardial injury received fewer therapies than patients with type 1 or type 2 myocardial infarction ( $P < 0.001$  for all).

### Outcomes by classification

The primary outcome of subsequent myocardial infarction or cardiovascular death occurred in 17% (863/4,981) of patients with type 1 myocardial infarction, and in 14% (162/1,121) with type 2 myocardial infarction, 16% (273/1,676) with acute myocardial injury, and 16% (207/1,287) with chronic myocardial injury, respectively (**Table S2**). When compared to those without myocardial injury, the risk and rate of the primary outcome was highest in patients with type 1 myocardial infarction (**Figure 2**, cause-specific Hazard Ratio [csHR] 5.64, 95%CI 5.12 to 6.22), but increases were also observed in patients with type 2 myocardial infarction (csHR 3.50, 95%CI 2.94 to 4.15), acute myocardial injury (csHR 4.38, 95%CI 3.80 to 5.05) and chronic myocardial injury (csHR 3.88, 95%CI 3.31 to 4.55, **Figure 3**, **Table S3**). The rate of future type 1 or 4b myocardial infarction at one year was highest in those with an index type 1 myocardial infarction (9%, 466/4,981), and lower in those with type 2 myocardial infarction (5%, 51/1,1121), acute (3%, 56/1,676) or chronic myocardial injury (4%, 57/1,287).

Death from any cause occurred in 9% (4,367/48,282) of patients, with those with acute myocardial injury at highest risk (**Figure S2**). The proportion of deaths from cardiovascular and non-cardiovascular causes differed across diagnostic categories (**Figure 4**). The risk and rate of death from a non-cardiovascular cause was highest in patients with acute myocardial injury (**Figure 2**, csHR 2.65, 95%CI 2.33 to 3.01), type 2 myocardial infarction (csHR 1.72, 95%CI 1.44 to 2.06) and chronic myocardial injury (csHR 2.06, 95%CI 1.77 to 2.40), and was lowest in patients with type 1 myocardial infarction (csHR 0.83, 95%CI 0.72 to 0.96).

### Implementation of the high-sensitivity assay

In the implementation phase, the use of high-sensitivity troponin increased the diagnosis of type 1 myocardial infarction by 11% (510/4,471), type 2 myocardial infarction by 22% (205/916), acute myocardial injury by 36% (443/1,233) and chronic myocardial injury by 43% (389/898). Despite increases in the use of anti-platelet and anticoagulant therapies (43% *versus* 61%) and coronary revascularisation (35% *versus* 44%), there was no reduction in the primary outcome in patients with type 1 myocardial infarction (csHR 1.00, 95%CI 0.82 to 1.21, **Table S4 and S5, Figure S3 and S4**). Implementation was not associated with additional treatment or improvement in outcomes for patients with type 2 myocardial infarction or myocardial injury (**Table S4 and S5, Figure S3 and S4**).



### Discussion

In a randomised controlled trial, we evaluated the effect of implementing a high-sensitivity cardiac troponin I assay and the recommendations of the Universal Definition of Myocardial Infarction on clinical outcomes in consecutive patients with suspected acute coronary syndrome. Whilst the majority of patients had a diagnosis of type 1 myocardial infarction, the introduction of high-sensitivity troponin testing led to a disproportionate increase in the diagnosis of type 2 myocardial infarction and myocardial injury. All patients with myocardial injury or infarction were at increased risk of future myocardial infarction or cardiovascular death, with those with type 1 myocardial infarction at highest risk. Despite modest increases in coronary revascularisation and preventative therapies in patients with type 1 myocardial infarction, there was no reduction in future cardiovascular events. In patients with type 2 myocardial infarction or myocardial injury, cardiovascular event rates and future risk was similar to patients with type 1

myocardial infarction, despite a marked increase in non-cardiovascular death. Here, we observed no change in cardiovascular investigations or treatments, and outcomes were similarly unchanged.

The observed excess in mortality in patients with type 2 myocardial infarction or myocardial injury is consistent with prior observational studies.<sup>8,11,13,19-28</sup> Patients with acute myocardial injury were at highest risk of non-cardiovascular death, with more than a third occurring within 30 days due to pneumonia, an infective exacerbation of chronic obstructive pulmonary disease or sepsis. In a model attempting to account for this competing risk of non-cardiovascular death, patients with type 2 myocardial infarction or myocardial injury had lower rates of cardiovascular events than those with type 1 myocardial infarction. Despite this, one in six had a myocardial infarction or died from a cardiovascular cause at one year; an event rate over three-fold higher than observed in those without evidence of myocardial injury.

Whilst high-sensitivity cardiac troponin clearly provides important prognostic information, implementation of testing into practice did not improve outcomes. This may be because in patients with type 2 myocardial infarction or myocardial injury, there is little consensus on how to investigate or treat either group. Even in those with type 1 myocardial infarction, where we have clear guidelines for investigation and treatment, we observed only modest increases in coronary angiography, anti-platelet or other preventative therapies. This may reflect clinician uncertainty in whether small increases in cardiac troponin are important, and if the benefits of invasive management outweigh the risks in this group. Indeed, our evidence base for the management of myocardial infarction largely predates the introduction of the Universal Definition, when the diagnostic threshold for myocardial infarction was almost ten-fold higher than the threshold implemented in this trial.

The lack of a specific cardiac biomarker to distinguish type 1 myocardial infarction, and the increasing frequency of type 2 myocardial infarction and myocardial injury poses challenges to clinicians in practice on a daily basis. As observed in this trial, type 2 myocardial infarction and myocardial injury are responsible for almost half of all elevations in cardiac troponin concentration, and have been shown to be more frequent than type 1 myocardial infarction in hospitalised patients over the age of 75.<sup>13</sup> Less than half of these patients are referred to cardiology, with the majority managed by general physicians,<sup>13</sup> and a lack of evidence has led to inconsistency in investigation and treatment.

The classification of type 2 myocardial infarction and myocardial injury is based on expert consensus, and to date no prospective clinical trials have evaluated the utility of this classification.<sup>29</sup> These conditions arise due to a wide range of pathologies including coronary or structural heart disease, arrhythmias, myocarditis and many non-cardiac conditions.<sup>8</sup> The latest guidance, requiring evidence of myocardial ischemia and oxygen supply-demand imbalance, has reduced the frequency of type 2 myocardial infarction. Our observations add to previous studies suggesting that any myocardial injury is prognostically important,<sup>11,30,31</sup> irrespective of whether myocardial ischemia was present, but strategies to guide further investigation and treatment in patients without type 1 myocardial infarction require prospective evaluation.

Whilst implementation of high-sensitivity troponin and the recommendations of the Universal Definition did not improve outcomes here, the proposed framework of classification could be helpful as it encourages clinicians to consider the underlying mechanism of myocardial injury, and to not dismiss troponin elevation as mere bystander injury of no consequence.

The Fourth Universal Definition states patients with type 2 myocardial infarction should not have evidence of acute atherothrombosis, which may encourage clinicians to undertake

additional coronary investigations. If recognition of type 2 myocardial infarction or acute myocardial injury during another illness leads to the identification and treatment of previously unrecognised coronary or structural heart disease, it is plausible that cardiovascular outcomes could improve.<sup>16</sup> Indeed there is increasing evidence that the presence of obstructive coronary disease is the strongest predictor of future adverse cardiovascular outcomes.<sup>11,30,31</sup> Identification of those with chronic myocardial injury may also be useful, as this may indicate the presence of unrecognised stable cardiovascular disease. A prospective trial of coronary and cardiac imaging in type 2 myocardial infarction is in progress (DEMAND-MI, ClinicalTrials.gov NCT:03338504), and a randomised controlled trial of coronary investigation and targeted preventative therapy is planned.<sup>32</sup> These studies are an appropriate first step in the understanding of this heterogeneous group of patients and will help to refine the classification and provide clearer guidance for clinicians in practice. Randomised controlled trials of secondary prevention therapy are urgently required, but until such data are available to inform clinical guidelines, clinicians should carefully assess cardiovascular risk on an individual patient basis to guide investigation and secondary prevention.

There are several strengths and limitations of our study. This was a pre-specified secondary analysis of a randomised controlled trial, enrolling consecutive patients with suspected acute coronary syndrome across ten hospitals irrespective of age, sex, time of presentation and severity of illness. As such, we believe our results are generalisable and reflective of real-world clinical practice. Using all available clinical information, we reviewed and classified all patients according to the latest recommendations from the Universal Definition of Myocardial Infarction to ensure our findings are relevant to current practice. Where there was consensus amongst the adjudication panel that there was insufficient clinical information to make a definitive diagnosis,

due to missing admission or discharge letters, we did not attempt to adjudicate the diagnosis (1,245/10,360, 12%). We had access to all other information including past medical history, clinical investigations, management and outcomes, and provide data for all primary and secondary outcomes in this group within the data supplement (*Table S1 and S2*). Our trial population was restricted to patients who had cardiac troponin measured for suspected acute coronary syndrome, and we acknowledge that the prevalence of type 2 myocardial infarction and myocardial injury may differ in consecutive patients where cardiac troponin was measured for any reason.<sup>(33,34)</sup> Whilst we implemented the recommendations of the Third Universal Definition in our trial, as the Fourth Universal Definition provides no additional guidance on the investigation or treatment of patients with type 2 myocardial infarction or myocardial injury, we think it is unlikely that outcomes would differ had this guideline been in place at the start of the trial. Whilst there was substantial overall agreement between adjudicators for the classification of myocardial injury and infarction, we recognize that agreement was only moderate for the classification of type 2 myocardial infarction or myocardial injury. In addition, we acknowledge that investigations and treatments were undertaken at the discretion of the treating clinician there is a risk of diagnostic misclassification. A formal comparison of the adjudicated diagnosis and ICD-10 coded clinical diagnosis is planned. Serial cardiac troponin measurements were only undertaken in 77% (6,983/9,115) of patients, which has particular relevance to the distinction between acute and chronic myocardial injury. Consequently, we considered both diagnoses as a single entity when comparing outcomes by study phase to avoid selection bias.

In conclusion, implementation of the recommendations of the Universal Definition of Myocardial Infarction identified patients at high risk of cardiovascular and non-cardiovascular events, but was not associated with consistent increases in treatment or improved outcomes.



Effective strategies for the investigation and treatment of patients with type 2 myocardial infarction and myocardial injury are required if we are to improve outcomes.

## Authors

Andrew R. Chapman, MD<sup>1</sup>; Philip D. Adamson, MD<sup>1,2</sup>; Anoop S.V. Shah, MD<sup>1</sup>;  
 Atul Anand, MD<sup>1</sup>; Fiona E. Strachan, PhD<sup>1</sup>; Amy V. Ferry, BSc<sup>1</sup>; Kuan Ken Lee, MD<sup>1</sup>;  
 Colin Berry, MD<sup>3</sup>; Iain Findlay, MD<sup>4</sup>; Anne Cruikshank, MD<sup>5</sup>; Alan Reid, MSc<sup>5</sup>;  
 Alasdair Gray, MD<sup>6</sup>; Paul O. Collinson, MD<sup>7</sup>; Fred Apple, PhD<sup>8</sup>; David A. McAllister, MD<sup>9</sup>;  
 Donogh Maguire, MD<sup>10</sup>; Keith A.A. Fox, MD<sup>1</sup>; Catalina A. Vallejos PhD<sup>11,12</sup>;  
 Catriona Keerie, MSc<sup>13,14</sup>; Christopher J. Weir, PhD<sup>13,14</sup>; David E. Newby, MD<sup>1</sup>;  
 Nicholas L. Mills, MD<sup>1,14</sup>; on behalf of the High-STEACS Investigators<sup>†</sup>



<sup>1</sup>BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK;

<sup>2</sup>Christchurch Heart Institute, University of Otago, Christchurch, NZ; <sup>3</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; <sup>4</sup>Department of Cardiology, Royal Alexandra Hospital, Paisley, UK; <sup>5</sup>Department of Biochemistry, Queen Elizabeth University Hospital, Glasgow, UK; <sup>6</sup>Emergency Medicine Research Group Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK; <sup>7</sup>Departments of Clinical Blood Sciences and Cardiology, St George's, University Hospitals NHS Trust and St George's University of London, London, UK; <sup>8</sup>Department of Laboratory Medicine and Pathology, Hennepin Healthcare/Hennepin County Medical Center & University of Minnesota, Minneapolis, MN; <sup>9</sup>Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK; <sup>10</sup>Emergency Medicine Department, Glasgow Royal Infirmary, Glasgow, UK; <sup>11</sup>MRC Human Genetics Unit,

University of Edinburgh, Edinburgh UK; <sup>12</sup>The Alan Turing Institute, London, UK; <sup>13</sup>Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK; <sup>14</sup>Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

†Listed in the online data supplement.

### Sources of Funding

This trial was funded by a Special Project Grant from the British Heart Foundation (SP/12/10/29922) with additional support from a British Heart Foundation-Turing Cardiovascular Data Science Award (BCDSA/100003) and British Heart Foundation Research Excellence Award (RE/18/5/34216; RE/18/6/3421). ARC, NLM and DEN are supported by Clinical Research Training Fellowship (FS/16/75/32533), Butler Senior Clinical Research Fellowship (FS/16/14/32023) and Chair (CH/09/002) awards from the British Heart Foundation. ARC also receives support from a Starter Grant for Clinical Lecturers from the Academy of Medical Sciences (SGL021\1075). CJW was supported by the National Health Service (NHS) in Lothian through the Edinburgh Clinical Trials Unit. Abbott Laboratories provided cardiac troponin assay reagents, calibrators, and controls without charge. The funders played no role in the design, conduct, data collection, analysis or reporting of the trial.

### Acknowledgments

The High-STEACS Investigators contributed to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work. They were involved in drafting the manuscript and revising it, and have given final approval of the version to be published. The High-STEACS investigators are accountable for the work. We would like to thank researchers

from the Emergency Medicine Research Group Edinburgh for their support during the conduct of this trial.

### **Disclosures**

ASVS and ARC have received honoraria from Abbott Diagnostics. NLM has received honoraria from Abbott Diagnostics, Siemens Healthineers, and Singulex and the University of Edinburgh has received research grants from Abbott Diagnostics and Siemens Healthineers. FSA has received honoraria (advisory board) from Siemens Healthineers and LumiraDx; non-salaried research funding through research foundation from Abbott Diagnostics, Abbott PC, Beckman Coulter, Siemens Healthineers, Quidel, Ortho-Clinical Diagnostics, Roche Diagnostics; Board of Directors HyTest. CB is named on institutional research and/or consultancy agreements between the University of Glasgow and Abbot Vascular, AstraZeneca, Coroventis, Corstem, GSK, Heartflow, Menarini, Neosoft, Novartis, Philips, and Siemens Healthcare. These companies had no involvement in this manuscript.

## References

1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. *Eur Heart J* 2012; 33: 2551-2567.
2. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2019; 40: 237-269.
3. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. *Circulation* 2007;116: 2634-2653.
4. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan FE et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. *Bmj* 2015; 350: g7873.
5. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. *Clin Chem* 2012; 58: 54-61.
6. Chapman AR, Lee KK, McAllister DA, Cullen L, Greenslade JH, Parsonage W, Worster A, Kavsak PA, Blankenberg S, Neumann J, et al. Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. *Jama* 2017; 318: 1913-1924.
7. Wu AHB, Christenson RH, Greene DN, Jaffe AS, Kavsak PA, Ordonez-Llanos J, Apple FS. Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem* 2018;64: 645-655.
8. Januzzi JL, Sandoval Y. The Many Faces of Type 2 Myocardial Infarction. *J Am Coll Cardiol* 2017; 70: 1569-1572.
9. Shah ASV, Sandoval Y, Noaman A, Sexter A, Vaswani A, Smith SW, Gibbins M, Griffiths M, Chapman AR, Strachan FE et al. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. *Bmj* 2017; 359: j4788.
10. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. *Heart* 2017; 103: 10-18.
11. Chapman AR, Shah ASV, Lee KK, Anand A, Francis O, Adamson PD, McAllister DA, Strachan FE, Newby DE, Mills NL. Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury. *Circulation* 2018; 137: 1236-1245.
12. Alpert JS, Thygesen KA. The Case for a Revised Definition of Myocardial Infarction-The Ongoing Conundrum of Type 2 Myocardial Infarction vs Myocardial Injury. *JAMA Cardiol* 2016; 1: 249-250.
13. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, Anand A, Fersia O, Joshi NV et al. Sensitive troponin assay and the classification of myocardial infarction. *Am J Med* 2015; 128: 493-501.e3.
14. Shah ASV, Anand A, Strachan FE, Ferry AV, Lee KK, Chapman AR, Sandeman D, Stables CL, Adamson PD, Andrews JPM et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. *Lancet* 2018; 392:919-928.
15. Scottish Intercollegiate Guidelines Network (SIGN). Acute coronary syndromes. SIGN publication no. 93. Date published February 2013. Date accessed January 2019. Available online

at <https://www.acutemedicine.org.uk/wp-content/uploads/2015/12/SIGN-Acute-Coronary-Syndrome-2013.pdf>.

16. Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. *N Engl J Med* 2018; 379: 924-933.
17. Andersen PK, Geskus RB, de Witte T, Putter H. Competing risks in epidemiology: possibilities and pitfalls. *Int J Epidemiol* 2012; 41: 861-870.
18. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk; *Annals of Statistics*. 1998;16:1141-1154
19. Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver Be, Hu Y, Jacoby K et al. Type 1 and 2 Myocardial Infarction and Myocardial Injury: Clinical Transition to High-Sensitivity Cardiac Troponin I. *Am J Med* 2017; 130: 1431-1439.e4.
20. Smilowitz NR, Subramanyam P, Gianos E, Reynolds HR, Shah B, Sedlis SP. Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction. *Coron Artery Dis* 2018; 29: 46-52.
21. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Hosbond S, Jangaard N, Diederichsen AC, Thygesen K, Mickley H. Prognostic Impact of Myocardial Injury Related to Various Cardiac and Noncardiac Conditions. *Am J Med* 2016; 129: 506-514.e1.
22. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, Gerko O, Hallas J, Thygesen K, Mickley H. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. *Am J Med* 2014; 127: 295-302.
23. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N, Hosbond S, Diederichsen AC, Thygesen K, Mickley H. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. *Am J Med* 2016; 129: 446.e5-.e21.
24. Gaggin HK, Liu Y, Lyass A, van Kimmenade RR, Motiwala SR, Kelly NP, Mallick A, Gandhi PU, Ibrahim NE, Simon ML et al. Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. *Circulation* 2017; 135: 116-127.
25. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). *Circulation* 2012; 125: 577-583.
26. Roos A, Sartipy U, Ljung R, Holzmann MJ. Relation of Chronic Myocardial Injury and Non-ST-Segment Elevation Myocardial Infarction to Mortality. *Am J Cardiol* 2018; 122: 1989-1995.
27. Neumann JT, Sorensen NA, Rubsamen N, Ojeda F, Renné T, Qaderi V, Teltrap E, Kramer S, Quantius L, Zeller T et al. Discrimination of patients with type 2 myocardial infarction. *Eur Heart J* 2017; 38: 3514-3520.
28. Kadesjo E, Roos A, Siddiqui A, Desta L, Lundback M, Holzmann MJ. Acute versus chronic myocardial injury and long-term outcomes. *Heart*. 2019. ePub ahead of print. doi: 10.1136/heartjnl-2019-315036
29. Sandoval Y, Thygesen K. Myocardial Infarction Type 2 and Myocardial Injury. *Clin Chem* 2017; 63: 101-107.

30. Baron T, Hambraeus K, Sundstrom J, Erlinge D, Jernberg T, Lindahl B. Impact on Long-Term Mortality of Presence of Obstructive Coronary Artery Disease and Classification of Myocardial Infarction. *Am J Med* 2016; 129: 398-406.
31. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbacher D, Sabti Z, Puelacher C, Rubini Gimenez M, Kozhuharov N et al. Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction. *J Am Coll Cardiol* 2017; 70: 1558-1568.
32. Lambrakis K, French J, Scott IA, Briffa T, Brieger D, Farkouh ME, White H, Chuang AM, Tiver K, Quinn S, Kaambwa B et al. The appropriateness of coronary investigation in myocardial injury and Type 2 myocardial infarction (ACT-2): A randomized trial design. *Am Heart J* 2019; 208: 11-20
33. DeFilippis AP, Chapman AR, Mills NL, de Lemos JA, Arbab-Zadeh A, Newby LK, Morrow DA. Assessment and Treatment of Patients with Type 2 Myocardial Infarction and Acute Non-Ischemic Myocardial Injury. *Circulation*. 2019. ePub ahead of print. <https://doi.org/10.1161/CIRCULATIONAHA.119.040631>
34. McCarthy CP, Raber I, Chapman AR, Sandoval Y, Apple FS, Mills NL, Januzzi JL. Myocardial Injury in the Era of High-Sensitivity Cardiac Troponin Assays: A Practical Approach for Clinicians. *JAMA Cardiol*. 2019. ePub ahead of print. doi:10.1001/jamacardio.2019.2724



# Circulation

**Table 1.** Characteristics of the Trial Participants Classified by the Fourth Universal Definition of Myocardial Infarction

	All patients	No myocardial injury	Type 1 myocardial infarction	Type 2 myocardial infarction	Acute myocardial injury	Chronic myocardial injury
No. of participants	48,282	37,922	4,981	1,121	1,676	1,287
Age (years), mean (SD)	61 (17)	58 (17)	68 (14)	74 (14)	75 (15)	74 (15)
Men, n (%)	25,720 (53)	20,351 (54)	2,995 (60)	501 (45)	664 (40)	536 (42)
<b>Phase</b>						
Validation	18,978 (39)	14,862 (39)	1,794 (36)	405 (36)	683 (41)	498 (39)
<b>Presenting symptom*</b>						
Chest pain, n (%)	34,540 (81)	28,091 (84)	4,061 (89)	749 (73)	569 (38)	559 (49)
Dyspnoea, n (%)	2,175 (5)	1,107 (3)	171 (4)	116 (11)	372 (25)	235 (21)
Palpitation, n (%)	1,269 (3)	991 (3)	17 (<1)	67 (6)	97 (6)	42 (4)
Syncope, n (%)	2,495 (6)	1,809 (5)	102 (2)	38 (4)	240 (16)	179 (16)
Other, n (%)	2,188 (5)	1,458 (4)	221 (5)	61 (6)	217 (15)	116 (10)
<b>Past medical history</b>						
Myocardial infarction, n (%)	4,214 (9)	2,835 (7)	667 (13)	163 (15)	161 (10)	205 (16)
Ischemic heart disease, n (%)	11,912 (25)	8,455 (22)	1,519 (30)	454 (40)	509 (30)	492 (38)
Cerebrovascular disease, n (%)	2,949 (6)	1,915 (5)	368 (7)	135 (12)	192 (11)	167 (13)
Diabetes mellitus, n (%)	3,518 (7)	2,040 (5)	802 (16)	147 (13)	208 (12)	164 (13)
Heart failure hospitalisation, n (%)	4,322 (9)	2,159 (6)	792 (16)	292 (26)	410 (24)	363 (28)
<b>Previous revascularisation</b>						
PCI, n (%)	3,682 (8)	2,744 (7)	487 (10)	97 (9)	94 (6)	128 (10)
CABG, n (%)	782 (2)	534 (1)	105 (2)	32 (3)	45 (3)	34 (3)
<b>Medications at presentation</b>						
Aspirin, n (%)	13,163 (27)	9,462 (25)	1,694 (34)	471 (42)	608 (36)	452 (35)
Dual anti-platelet therapy, n (%)†	1,605 (3)	1,103 (3)	233 (5)	64 (6)	71 (4)	68 (5)
Statin, n (%)	19,366 (40)	14,106 (37)	2,377 (48)	632 (56)	852 (51)	686 (53)
ACE inhibitor or ARB, n (%)	15,618 (32)	11,285 (30)	1,995 (40)	514 (46)	692 (41)	579 (45)
Beta-blocker, n (%)	13,173 (27)	9,566 (25)	1,598 (32)	489 (44)	564 (34)	460 (36)
Oral anti-coagulant, n (%)‡	3,253 (7)	2,158 (6)	292 (6)	170 (15)	225 (13)	198 (15)
<b>Electrocardiogram§</b>						

Normal	-	-	1,578 (32)	201 (18)	400 (24)	363 (28)
Myocardial ischemia	-	-	1,872 (38)	383 (34)	112 (7)	75 (6)
ST-segment elevation	-	-	870 (17)	36 (3)	38 (2)	40 (3)
ST-segment depression	-	-	865 (17)	278 (25)	87 (5)	56 (4)
T-wave inversion	-	-	780 (16)	166 (15)	128 (8)	148 (11)
<b>Physiological parameters</b> §						
Heart rate, beats per minute	-	-	79 (20)	105 (35)	94 (29)	85 (24)
Systolic blood pressure, mmHg	-	-	142 (28)	132 (30)	136 (31)	137 (29)
<b>Hematology and clinical chemistry</b>						
Haemoglobin, g/L	136 (22)	137 (20)	136 (22)	126 (29)	128 (25)	127 (24)
eGFR, ml/min	54 (13)	56 (10)	51 (14)	46 (15)	45 (16)	45 (17)
Peak hs-cTnI, ng/L	4 [2, 16]	3 [1, 6]	855 [104, 6775]	125 [48, 604]	74 [37, 307]	55 [34, 145]

Presented as mean (SD), median (inter-quartile range), or number (%). There were significant differences ( $P < 0.001$ ) between groups for all co-variables. P values obtained from group-wise comparisons using Chi-square, Kruskal Wallis or one way analysis of variance tests as appropriate. Cell counts  $< 5$  are redacted in line with regulatory approvals.

\*Presenting symptom was missing in 5,615 (12%) patients.

†Two medications from aspirin, clopidogrel, prasugrel or ticagrelor. ‡Includes warfarin or novel oral anti-coagulants.

§ Electrocardiographic findings and physiological parameters only reported for those with elevation in cardiac troponin concentrations.

Abbreviations: ACE = angiotensin converting enzyme; ARB = angiotensin receptor blockers; eGFR = estimated glomerular filtration rate; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.



**Table 2.** Management During Index Hospital Admission Stratified by the Fourth Universal Definition of Myocardial Infarction

	All patients	No myocardial injury	Type 1 myocardial infarction	Type 2 myocardial infarction	Acute myocardial injury	Chronic myocardial injury
No. of participants	48,282	37,922	4,981	1,121	1,676	1,287
Duration of stay, hrs	9 [3, 39]	5 [3, 22]	75 [41, 126]	96 [37, 201]*	114 [23, 284]*	116 [38, 290]*
ACS treatment in ED	3,458 (34)	<5 (<1)	2,717 (55)	294 (26)*	199 (12)*	209 (16)*
New anti-platelet agent	5,865 (12)	1,771 (5)	3,354 (67)	209 (19)*	165 (10)*	185 (14)*
New dual anti-platelet therapy‡	3,967 (8)	584 (2)	2,969 (60)	116 (10)*	76 (5)*	94 (7)*
Coronary angiography†	3,786 (8)	515 (1)	2,928 (59)	115 (10)*	63 (4)*	72 (6)*
PCI	2,370 (5)	267 (1)	2,021 (41)	17 (2)*	<5 (<1)*	6 (<1)*
New ACE inhibitor or ARB	2,711 (6)	766 (2)	1,577 (32)	104 (9)*	92 (5)*	96 (7)*
New beta-blocker	4,416 (9)	1,857 (5)	1,878 (38)	219 (20)*	175 (10)*	153 (12)*
New statin therapy	3,061 (6)	1,027 (3)	1,764 (35)	68 (6)*	58 (3)*	80 (6)*
New oral anticoagulant	1,477 (3)	834 (2)	129 (3)	209 (19)*	153 (9)*	78 (6)*

Values are number (%) or median (inter-quartile range). There were significant differences ( $P < 0.001$ ) between groups for all co-variables. P values obtained from group-wise comparisons using Chi-square or Kruskal Wallis as appropriate.

Abbreviations: ACE = angiotensin converting enzyme; ACS = acute coronary syndrome; ARB = angiotensin receptor blockers; CABG = coronary artery bypass grafting; ED = Emergency Department; PCI = percutaneous coronary intervention. Cell counts <5 are redacted in line with regulatory approvals.

\* P value <0.001 in post-hoc analysis with type 1 myocardial infarction as the reference group, with Bonferroni correction for multiple testing.

† Angiography and revascularisation within 30 days of presentation

‡ Two medications from aspirin, clopidogrel, prasugrel or ticagrelor

## Figure Legends

**Figure 1.** Consort diagram with identification of the study population by classification, and proportion identified by the contemporary troponin assay (cTnI) or reclassified by the high-sensitivity assay (hs-cTnI). Serial cardiac troponin concentrations were available in 77% (6,983/9,115) of patients with myocardial injury.


**Figure 2.** Cumulative incidence curves for the primary outcome of type 1 or 4b myocardial infarction or cardiovascular death, and competing risk of non-cardiovascular death, stratified by type 1 myocardial infarction (red), type 2 myocardial infarction (gold), acute myocardial injury (dark blue), chronic myocardial injury (light blue) and no myocardial injury (green) with table of number at risk. Estimates obtained from a cumulative incidence function.

**Figure 3.** Forest plot of the primary outcome (type 1 or 4b myocardial infarction or cardiovascular death) and non-cardiovascular death in the trial population stratified by index diagnosis; type 1 myocardial infarction (red), type 2 myocardial infarction (gold), acute myocardial injury (dark blue) and chronic myocardial injury (light blue), relative to those with no myocardial injury. Adjusted cause-specific hazard ratios (csHR) obtained from multivariable cox regression models including adjustment for age, sex, a history of ischemic heart disease or diabetes mellitus, renal function, time of presentation from the start date of the trial, season, phase of the trial and site of recruitment (as a random effect). In this model the competing event or time of censor are both considered as independent outcomes.


**Figure 4.** Flow diagram (alluvial plot) illustrating the frequency of cause of death grouped by classification of myocardial infarction and cardiovascular or non-cardiovascular causes. Type 1 myocardial infarction (red), type 2 myocardial infarction (gold), acute myocardial injury (dark blue) and chronic myocardial injury (light blue). All causes of death which occurred in five or more patients are included, with the width of band indicating the relative size of the population.



# Circulation




Circulation




Type 1 MI	4981	4397	4250	4165	4981	4576	4432	4322
Type 2 MI	1121	1044	1004	984	1121	993	938	897
Acute Myocardial Injury	1676	1520	1459	1429	1676	1328	1224	1158
Chronic Myocardial Injury	1287	1186	1141	1098	1287	1087	1011	944
No Myocardial Injury	37922	37569	37381	37190	37922	37084	36613	36186

Myocardial infarction or cardiovascular death

Non-cardiovascular death



6102, retrieved from <http://ahajournals.org> by on November 4, 2019



American Heart Association